natgillin/translations-raw huggingface dataset:
The highest dose of Lonsurf administered in clinical trials was 180 mg/m2 per day.
Najviša doza Lonsurfa koja se primjenjivala u kliničkim ispitivanjima bila je 180 mg/m2 na dan.
The primary site of disease was colon (62%) or rectum (38%).
Primarno sijelo tumora je bio kolon (62%) ili rectum (38%).
Frequency groups are defined by the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); and uncommon (≥1/1,000 to < 1/100).
Skupine prema učestalosti definirane su na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); i manje često (≥1/1000 i < 1/100).
The majority of recovered radioactivity was eliminated into urine (55% of the dose) within 24 hours, and the excretion into faeces and expired air was less than 3% for both.
Većina radioaktivnosti je bila eliminirana urinom (55% doze) unutar 24 sata, a izlučivanje fecesom i izdahnutim zrakom je bilo manje od 3% za oba načina.
If you forget to take Lonsurf
Ako ste zaboravili uzeti Lonsurf
As for the other exposure parameters of trifluridine and tipiracil hydrochloride, those appeared to be dose proportional.
Kao i kod drugih parametara izloženosti trifluridinu i tipiracilkloridu i ovi su čini se proporcionalni dozi.
The primary anticipated complication of an overdose is bone marrow suppression.
Glavna očekivana komplikacija predoziranja je supresija koštane srži.
For low albumin values ranging from 2.2 to 3.5 g/dL, the corresponding clearance values range from 4.2 to 3.1 L/h.
Za niske razine vrijednosti albumina od 2,2 do 3,5 g/dl, odgovarajuće vrijednosti klirensa iznose od 4,2 do 3,1 l/h.
Les Laboratoires Servier 50 rue Carnot 92284 Suresnes Cedex France
Les Laboratoires Servier 50 rue Carnot 92284 Suresnes Cedex Francuska
• a reduced number of certain types of white blood cells (neutropenia) which are important for protecting the body against bacterial or fungal infections.
• smanjenje broja određenih vrsta bijelih krvnih stanica (neutropenija) koje su važne za zaštitu tijela od bakterijskih ili gljivičnih infekcija.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolesnici s rijetkim nasljednim poremećajem nepodnošenja galaktoze, potpunim nedostatkom laktaze ili malapsorpcijom glukoze i galaktoze ne smiju uzimati ovaj lijek.
If you take more Lonsurf than you should, talk to a doctor or go to a hospital straight away.
Ako ste uzeli više lijeka Lonsurf nego što ste trebali, obratite se liječniku ili odmah otiđite u bolnicu.
• feeling of spinning (vertigo)
• osjećaj vrtoglavice (vertigo)
If you are pregnant or breast-feeding, or if you think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.
• feeling of being cold
• osjećaj hladnoće
• blood test result indicating inflammation (C-Reactive Protein increased)
• krvne pretrage koje upućuju na upalu (povišena razina C reaktivnog proteina)
DATE OF REVISION OF THE TEXT MM/YYYY
DATUM REVIZIJE TEKSTA MM/GGGG
Pharmacotherapeutic group: antineoplastic agents, antimetabolites, ATC code: L01BC59 Mechanism of action
Farmakoterapijska skupina: antineoplastici, antimetaboliti, ATK oznaka: L01BC59
What you need to know before you take Lonsurf
Što morate znati prije nego počnete uzimati Lonsurf
Recommended dose adjustments
Preporučene prilagodbe doze
Feeling of body temperature change Xerosis
Osjećaj promjene tjelesne temperature
In clinical studies Lonsurf was administered within 1 hour after completion of the morning and evening meals (see section 4.2).
Lonsurf je primjenjivan unutar 1 sata nakon završetka jutarnjih i večernjih obroka (vidjeti dio 4.2).
ANNEX IV CONCLUSIONS ON THE REQUEST FOR ONE-YEAR MARKETING PROTECTION PRESENTED BY THE EUROPEAN MEDICINES AGENCY
ZAKLJUČCI EUROPSKE AGENCIJE ZA LIJEKOVE ZAHTJEVU ZA JEDNOGODIŠNJU ZAŠTITU STAVLJANJA LIJEKA U PROMET
Progression-Free Survival Number of Progression or Death, N (%)
Preživljenje bez progresije (PFS) Broj progresija ili smrtnih slučajeva, N (%)
• Neutropenia (very common), febrile neutropenia (common) and septic shock (uncommon).
• Neutropenija (vrlo često), febrilna neutropenija (često) i septički šok (manje često).
Each pack contains 20, 40 or 60 film-coated tablets.
Pakiranje sadrži 20, 40 ili 60 filmom obloženih tableta.
Eighteen percent (18%, N = 144) of all randomised patients received regorafenib prior to randomisation.
Osamnaest posto (18%, N=144) svih randomiziranih bolesnika je primilo regorafenib prije randomizacije.
• Tipiracil stops the trifluridine from being broken down by the body, helping trifluridine to work longer.
• Tipiracil spriječava da se trifluridin razgradi u tijelu, i na taj način trifluridin dulje djeluje.
• Take within 1 hour after your morning and evening meal.
• Uzmite lijek unutar sat vremena nakon jutarnjeg i večernjeg obroka.
Also some other medicines can affect the way Lonsurf works.
Također, neki lijekovi mogu utjecati na učinak lijeka Lonsurf.
If you or your partner becomes pregnant during this time, you must talk to your doctor or pharmacist straight away.
Ako Vi ili Vaša partnerica ostanete trudni tijekom tog vremena, odmah se obratite svom liječniku ili ljekarniku.
Tablets per dose (2x daily)
Tablete po dozi (2x dnevno)
Urinary tract infection Gingivitis
Infekcija urinarnog trakta Gingivitis
Thus trifluridine and tipiracil hydrochloride are not expected to cause or be subject to a significant medicinal product interaction mediated by CYP.
Prema tome za trifluridin i tipiracilklorid se ne očekuje da uzrokuju ili da budu podložni značajnim interakcijama lijeka posredovanih CYP-om.
BSA (m2)
PT (m2)
Lonsurf contains two different active substances: trifluridine and tipiracil.
Lonsurf sadrži dvije djelatne tvari: trifluridin i tipiracil.
c. Hand-foot skin reaction.
c. Kožna reakcija šaka-stopalo.
The incidences of Grade ≥3 neutropenia were higher in the high trifluridine AUC group (47.8%) compared with the low-trifluridine AUC group (30.4%).
Incidencija neutropenije 3. stupnja ili više bila je veća u AUC skupini s visokim trifluridinom (47,8%) u usporedbi sa skupinom s niskim trifluridinom (30,4%).
≥ 75 × 109/L a Resumption criteria applied to the start of the next cycle for all patients regardless of whether or not the interruption criteria were met.
≥ 75 × 109/L a Kriteriji za nastavak primjene se primjenjuju na početku svakog idućeg ciklusa kod svih bolesnika bez obzira da li su imali prethodni prekid terapije.
You must not become pregnant while taking this medicine.
Ne smijete ostati trudni dok uzimate ovaj lijek jer može štetiti
The following side effects may happen with this medicine:
Sljedeće nuspojave se mogu javiti uz primjenu ovog lijeka:
• Pulmonary embolism (uncommon): blood clots in lungs.
• Plućna embolija (manje često): krvni ugrušci u plućima.
• increased number of white blood cells called monocytes
• povećani broj bijelih krvnih stanica koje se nazivaju monociti
• shingles (pain and vesicular rash on skin over nerve tracts affected by nerve inflammation from herpes zoster virus)
• herpes zoster (bol i vezikularni osip na koži uzduž živčanih puteva pogođenih upalom živca s herpes zoster virusom)
The dosage is calculated according to body surface area (BSA) (see Table 1).
Doza se izračunava prema površini tijela (PT) (vidjeti Tablicu 1).
• Interstitial lung disease has been reported in patients receiving the medicine.
• Intersticijska bolest pluća zabilježena je u bolesnika koji su uzimali lijek.
Estimated (CrCl) was a significant covariate for CL/F in both final models of trifluridine and tipiracil hydrochloride.
Procjena klirensa (CrCl) je bila značajna kovarijanta za CL/F u oba finalna modela trifluridina i tipiracilklorida.
• increased white blood cells
• povećani broj bijelih krvnih stanica
In vitro interaction studies
In vitro ispitivanje interakcije
The increases in the corpus luteum count and implanting embryo count observed in female rats at high doses were not considered adverse (see section 4.6).
Povećanje broja žutih tijela i povećan broj implantiranih embrija primijećen u ženki štakora pri visokim dozama se nije smatralo nuspojavom (vidjeti dio 4.6).
• CTCAE* non-haematologic Grade 3 or Grade 4 adverse reaction; except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or diarrhoea responsive to antidiarrhoeal medicinal products
• CTCAE* 3. ili 4. stupanj nehematološke nuspojave; osim za 3. stupanj mučnine i/ili povraćanja kontroliranog terapijom antiemeticima ili proljeva koji odgovara na terapiju antidijaroicima
Lonsurf is a type of cancer chemotherapy which belongs to the group of medicines called "cytostatic antimetabolite medicines".
Lonsurf je vrsta kemoterapije koja pripada skupini lijekova koji se nazivaju „citostatski antimetabolički lijekovi“.
Such medicinal products, if used concomitantly with Lonsurf, may compete with the effector, trifluridine, for activation via thymidine kinases.
Takvi lijekovi se, ukoliko se primjenjuju istodobno s Lonsurfom, mogu natjecati s efektorom, trifluridinom, za aktivaciju putem timidin kinaze.
Talk to your doctor or pharmacist before taking Lonsurf if:
Obratite se svom liječniku ili ljekarniku prije nego uzmete Lonsurf:
Menstrual disorder
Menstrualni poremećaji
Study treatment was administered orally twice daily after morning and evening meals for 5 days a week with 2 days rest for 2 weeks, followed by 14 days rest, repeated every 4 weeks.
Lijek se u ispitivanju uzimao peroralno dva puta dnevno, poslije jutarnjeg i večernjeg obroka tijekom 5 dana u tjednu s 2 dana pauze tijekom 2 tjedna, nakon čega je slijedila pauza od 14 dana, što se ponavljalo svaka 4 tjedna.
Sixty one percent (61%, N = 485) of all randomised patients received a fluoropyrimidine as part of their last treatment regimen prior to randomisation, of which 455 (94%) were refractory to the fluoropyrimidine at that time.
Šezdeset i jedan posto (61%, N=485) svih randomiziranih bolesnika je primilo fluoropirimidin u sklopu njihovog zadnjeg režima liječenja prije randomizacije, od kojih je 455 (94%) bilo refraktorno na fluoropirimidin u tom času.
Do not breast-feed if you are taking Lonsurf as it is not known whether Lonsurf passes into the mother's milk.
Nemojte dojiti tijekom liječenja s lijekom Lonsurf budući da nije poznato izlučuje li se Lonsurf u majčino mlijeko.
Patients continued therapy until disease progression or unacceptable toxicity (see section 4.2).
Bolesnici su nastavili s liječenjem sve do progresije bolesti ili neprihvatljive toksičnosti (vidjeti dio 4.2).
All changes, i.e., leukopenia, anaemia, bone marrow hypoplasia, atrophic changes in the lymphatic and haematopoietic tissues and the gastrointestinal tract, were reversible within 9 weeks of drug withdrawal.
Sve promjene, npr. leukopenija, anemija, hipoplazija koštane srži, atrofičke promjene na limfatičkom, hematopoetskom i gastrointestinalnom sustavu, su bile reverzibilne unutar 9 tjedana od prestanka davanja lijeka.
Based on the mechanism of action, trifluridine is suspected to cause congenital malformations when administered during pregnancy.
Na temelju mehanizma djelovanja, sumnja se da trifluridin može uzrokovati kongenitalne malformacije ako se primjeni tijekom trudnoće.
• abnormal increase or decrease in heart rate
• nenormalno povećanje ili smanjenje brzine otkucaja srca
Studies in animals have shown reproductive toxicity (see section 5.3).
Ispitivanja na životinjama pokazala su reproduktivnu toksičnosti (vidjeti dio 5.3).
However, there was no accumulation for tipiracil hydrochloride, and no further accumulation of trifluridine with successive cycles (Day 12 of Cycles 2 and 3) of administration of Lonsurf.
Međutim, nije došlo do akumulacije tipiracilklorida niti daljnje akumulacije trifluridina sa sljedećim ciklusima (12. dan ciklusa 2. i 3.) primjene Lonsurfa.
KRAS status was wild (49%) or mutant (51%) at study entry.
Na početku ispitivanja status gena KRAS bio je divlji tip (49%) ili mutacija (51%).
• blood test results indicating problems with clotting making you bleed more easily
• krvne pretrage koje upućuju na poteškoće sa zgrušavanjem krvi što ima za posljedicu da lakše krvarite
The recommended starting dose of Lonsurf in adults is 35 mg/m2/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or until unacceptable toxicity occurs (see section 4.4).
Preporučena početna doza Lonsurfa u odraslih je 35 mg/m2/po dozi, a primjenjuje se peroralno dva puta dnevno 1. do 5. dana i 8. do 12. dana svakog 28-dnevnog ciklusa sve dok se primjećuje korist ili dok se ne pojavi neprihvatljiva toksičnost (vidjeti dio 4.4).
There is limited data in Lonsurf treated patients aged 75 years and above (87 patients (10%) in pooled data of the RECOURSE and TAGS studies, of which 2 patients were 85 years or older).
Ograničeni su podaci u bolesnika liječenih Lonsurfom u dobi od 75 i više godina starosti (87 bolesnika (10%) u u skupnim podacima iz istraživanja RECOURSE i TAGS, od čega su 2 bolesnika bili stariji od 85 godina).
Primary cancer was gastric (71.0%) or gastroesophageal junction cancer (28.6%) or both (0.4%).
Primarno sijelo tumora je bio želudac (71,0%) ili gastroezofagealni spoj (28,6%) ili oboje (0,4%).
However, the incidence of serious, severe AEs and AEs leading to dose modification tends to increase with advancing levels of renal impairment.
Međutim, učestalost ozbiljnih, teških štetnih događaja i štetnih događaja koji dovode do prilagođavanja doze povećava se s povećanjem stupnja oštećenja bubrega.
Serious infections have been reported following treatment with Lonsurf (see section 4.8).
Ozbiljne infekcije prijavljene su nakon primjene Lonsurfa (vidjeti dio 4.8).
• burning sensation, unpleasant, increased or loss of sense of touch and other non-severe neurological troubles
• osjećaj pečenja, neugodan, pojačan osjećaj dodira ili njegov gubitak i druge neurološke poteškoće koje nisu teške
Talk to your doctor about whether to switch to a different HIV medicine.
Posavjetujte se sa svojim liječnikom je li potrebno promijeniti lijek za liječenje HIV-a.
Based upon limited data with a considerable variability, no statistically significant differences were observed in the pharmacokinetics in patients with normal hepatic function versus patients with mild or moderate hepatic impairment.
Temeljen ograničenih podataka sa značajnom varijabilnošću, nisu primjećene statistički značajne razlike u farmakokinetici bolesnika s normalnom jetrenom funkcijom i bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije.
It is currently unknown whether Lonsurf may reduce the effectiveness of hormonal contraceptives, and therefore women using hormonal contraceptives should add a barrier contraceptive method.
Za sada nije poznato smanjuje li Lonsurf učinkovitost hormonalane kontracepcije, pa žene koje uzimaju hormonske kontraceptive trebaju također koristiti mehaničku metodu kontracepcije.
The signs include chills, fever, sweating or other sign of bacterial or fungal infection (see section 2).
Znaci uključuju zimicu, vrućicu, znojenje ili druge znakove bakterijske ili gljivične infekcije (pogledajte dio 2),
(febrile neutropenia) and blood infection (septic shock) may occur
Mogu se pojaviti vrućica (febrilna neutropenija) i infekcija krvi (septički šok) kako posljedica neutropenije.
Complete blood cell counts must be obtained prior to initiation of therapy and as needed to monitor toxicity, but at a minimum, prior to each treatment cycle.
Prije početka liječenja potrebno je učiniti kompletnu krvnu sliku te je ponoviti prema potrebi za praćenje toksičnosti, te kao minimum prije svakog idućeg ciklusa.
The median number of prior lines of therapy for metastatic disease was 3.
Medijan prijašnjeg broja linija liječenja metastatskog karcinoma je bio 3.
Dose modifications (delay and/or reduction) should be applied as necessary (see section 4.2).
Prilagodbe doze (odgoda uzimanja i/ili smanjenje doze) se provode prema potrebi (vidjeti dio 4.2).
Treatment with Lonsurf plus BSC resulted in a statistically significant prolongation of PS <2 in comparison to placebo plus BSC.
Liječenje s Lonsurfom uz BSC rezultiralo je statistički značajnim produljenjem PS-a <2 u usporedbi s placebom uz BSC.
• Interrupt dosing until toxicity resolves to Grade 1 or baseline.
• Privremeno prekinuti doziranje dok se toksičnost ne povuče na 1. stupanj ili početnu vrijednost.
• When resuming dosing, decrease the dose level by 5 mg/m2/dose from the previous dose level (Table 4).
• Kod nastavka doziranja, smanjiti dozu za 5 mg/m2/dozi u odnosu na prethodnu dozu (Tablica 4).
The efficacy and safety of Lonsurf in metastatic colorectal cancer was compared between a high exposure group (>median) and a low-exposure group (≤median) based on the median AUC value of trifluridine.
Djelotvornost i sigurnost Lonsurfa u metastatskom kolorektalnom karcinomu uspoređena je između skupine s visokom izloženosti (> medijana) i skupine s niskom izloženosti (≤ medijana) u odnosu na medijan AUC vrijenosti trifluridina.
How to take You will take Lonsurf for 10 days during the first 2 weeks, and then have 2 weeks off.
Uzimati ćete Lonsurf 10 dana tijekom prva dva tjedna, zatim tijekom sljedeća dva tjedna lijek nećete uzimati.
Therefore, when using antiviral medicinal products that are human thymidine kinase substrates, monitor for possible decreased efficacy of the antiviral medicinal product, and consider switching to an alternative antiviral medicinal product that is not a human thymidine kinase substrate, such as lamivudine, didanosine and abacavir (see section 5.1).
Zbog toga, kod primjene antivirusnih lijekova koji su supstrati ljudske timidin kinaze, treba pratiti moguću smanjenu učinkovitost antivirusnog lijeka i treba razmisliti o prelasku na drugi antivirusni lijek koji nije supstrat ljudske timidin kinaze, kao što su lamivudin, didanozin i abakavir (vidjeti dio 5.1).
In RECOURSE and TAGS studies, 9.4% and 17.3% of patients in the Lonsurf group respectively received G-CSF mainly for therapeutic use.
U ispitivanjima RECOURSE i TAGS, 9,4% odnosno 17,3% bolesnika liječenih Lonsurfom primilo je G-CSF u terapijske svrhe.
Based on the population PK analysis, there is no clinically relevant effect of age, gender or race on the PK of trifluridine or tipiracil hydrochloride.
Temeljem analize populacijske PK, ne postoji klinički bitan utjecaj dobi, spola ili rase na PK trifluridina niti tipiracilklorida.
Patients with renal impairment should be monitored closely when being treated with Lonsurf; patients with moderate renal impairment should be more frequently monitored for haematological toxicities.
Bolesnici s oštećenjem bubrega moraju se pažljivo pratiti tijekom primjene Lonsurfa, a bolesnici s umjerenim oštećenjem bubrega se moraju češće pratiti zbog hematološke toksičnosti.
Trifluridine was shown to be genotoxic in a reverse mutation test in bacteria, a chromosomal aberration test in mammal-cultured cells, and a micronucleus test in mice.
Trifluridin je pokazao genotoksičnost ispitivanjem reverzne mutacije na bakterijama, ispitivanjem kromosomskih aberacija na kulturama stanica sisavaca i testu mikronukleusa u miša.
• vision troubles as blurred vision, double vision, decreased vision, cataracts
• poteškoće s vidom poput zamućenog vida, dvoslike, oslabljen vid, katarakta
There is no relevant use of Lonsurf in the paediatric population for the indications of metastatic colorectal cancer and metastatic gastric cancer.
Nema relevantne primjene Lonsurfa u pedijatrijskoj populaciji za indikacije metastatskog kolorektalnog karcinoma ili metastatskog karcinoma želuca.
There are no available data from the use of Lonsurf in pregnant women.
Nema dostupnih podataka o primjeni Lonsurfa u trudnica.
Lonsurf contains lactose.
Lonsurf sadrži laktozu.
This is because Lonsurf can affect the way some other medicines work.
To je zbog toga što Lonsurf može utjecati na učinak nekih lijekova.
Patients with severe renal impairment were not enrolled in the study.
Bolesnici s ozbiljno oštećenom funkcijom bubrega nisu uključeni u ispitivanje.
• athlete's foot - fungal infection of feet, yeast infections
• atletsko stopalo - gljivične infekcije stopala, gljivične infekcije
Serum albumin was found to significantly affect trifluridine clearance, with a negative correlation.
Potvrđeno je da vrijednost serumskog albumina značajno utječe na klirens trifluridina, s negativnom korelacijom.
Caution is required when using medicinal products that are human thymidine kinase substrates, e.g., zidovudine.
Potreban je oprez kod primjene lijekova koji su supstrati ljudske timidin kinaze npr. zidovudin.
Based on the population PK analysis, liver function parameters including alkaline phosphatase (ALP, 36-2322 U/L), aspartate aminotransferase (AST, 11-197 U/L), alanine aminotransferase (ALT, 5-182 U/L) , and total bilirubin (0.17-3.20 mg/dL) were not significant covariates for PK parameters of either trifluridine or tipiracil hydrochloride.
Temeljem analize populacijske PK, parametri funkcije jetre uključujući alkalnu fosfatazu (ALP, 362322 U/L), aspartat aminotransferazu (AST, 11-197 U/L), alanin aminotransferazu (ALT, 5-182 U/L) , i ukupni bilirubin (0,17-3,20 mg/dL), nisu bili značajne kovarijante za PK parametre niti za trifluridin niti tipiracilklorid.
There are no data available on the effects of Lonsurf on human fertility.
Ne postoje dostupni podaci o utjecaju Lonsurfa na plodnost u ljudi.
• accumulation of fluid in the lungs
• nakupljanje tekućine u plućima
All but 1 patient received bevacizumab, and all but 2 patients with KRAS wild type tumours received panitumumab or cetuximab.
Svi osim 1 bolesnika su primili bevacizumab, te svi osim 2 bolesnika s KRAS divljim tipom tumora su primili panitumumab ili cetuksimab.
The European Medicines Agency has waived the obligation to submit the results of studies with Lonsurf in all subsets of the paediatric population in refractory metastatic colorectal cancer and in refractory metastatic gastric cancer (see section 4.2 for information on paediatric use).
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja Lonsurfa u svim podskupinama pedijatrijske populacije s refraktornim metastatskim kolorektalnim karcinomom i s refraktornim metastatskim karcinomom želuca (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
• inflammation or increased acid in your stomach or gullet, reflux
• upala ili povećana razina kiseline u Vašem želucu ili jednjaku, refluks
It is unknown whether Lonsurf or its metabolites are excreted in human milk.
Nije poznato izlučuje li se Lonsurf ili njegovi metaboliti u majčino mlijeko.
Progression-free Survival Probability (%)
Vjerojatnost preživljenja bez progresije (%)
They are classified according to System Organ Class (SOC) and the appropriate Medical Dictionary for Regulatory (MedDRA) term is used to describe a certain drug reaction and its synonyms and related conditions.
System Organ Class), a prikladan MedDRA (Medical Dictionary for Regulatory Activities) pojam koristio se za opis određene nuspojave te njenih sinonima i srodnih stanja.
• viral infection
• virusne infekcije
• Severe gastrointestinal problems: abdominal pain (common), ascites (uncommon), colitis (uncommon), acute pancreatitis (uncommon), ileus (uncommon) and subileus (uncommon).
• Ozbiljne poteškoće s probavom: bolovi u trbuhu (često), ascites (manje često), kolitis (manje često), akutni pankreatitis (manje često), ileus (manje često) i subileus (manje često).
The most common adverse drug reactions (≥ 2%) in patients receiving Lonsurf that resulted in treatment discontinuation, dose reduction, dose delay, or dose interruption were neutropenia, anaemia, leukopenia, fatigue, thrombocytopenia, nausea and diarrhoea.
Najčešće nuspojave (≥ 2%) u bolesnika koji su primali Lonsurf, a koje su imale za posljedicu prekid liječenja, smanjenje doze, odgodu uzimanja doze ili privremeni prekid uzimanja bile su neutropenija, anemija, leukopenija, umor, trombocitopenija, mučnina i proljev.
If you are not sure, talk to your doctor before taking Lonsurf.
Ako niste sigurni, obratite se svom liječniku prije nego počnete uzimati Lonsurf.